Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial

BMC Cardiovascular Disorders

Research Article

Juan Cosín-Sales¹  Emilio Ruiz²  Francisco Pestana Araujo³  Gabriela Borrayo⁴  Carmen Suárez-Fernández⁵  Ricardo Gómez-Huelgas⁶  José M. Mostaza⁷  Carlos Brotons⁸ 

[1] Cardiology Service, Hospital Arnau de Vilanova, Valencia, Spain;Medicine Department, Facultad de Ciencias de la Salud, Universidad UCH-CEU, Alfara del Patriarca, Valencia, Spain;Corporate Medical Affairs Department, Ferrer Internacional, Barcelona, Spain;Hospital dos Lusíadas, Lisbon, Portugal;Instituto Mexicano del Seguro Social (IMSS), Ciudad de Mexico, Mexico;Internal Medicine Department Hospital de la Princesa, Madrid, Spain;Fundación Investigación Biomédica del Hospital de la Princesa, Madrid, Spain;Universidad Autónoma de Madrid (UAM), Madrid, Spain;Internal Medicine Department, Regional University Hospital of Málaga, Malaga, Spain;Biomedical Research Institute of Málaga (IBIMA), University of Málaga (UMA), Malaga, Spain;Internal Medicine Service, Hospital Carlos III, Madrid, Spain;Sardenya Primary Health Care Center, Barcelona, Spain;Biomedical Research Institute Sant Pau, Barcelona, Spain;

关键词: Cardiovascular disease;    Primary prevention;    Fixed-dose combination;    Polypill;    Non-inferiority trial;    Cardiovascular risk factors;   

DOI  :  10.1186/s12872-022-03013-w

 received in 2021-11-03, accepted in 2022-12-14,  发布年份 2022

来源: Springer

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

12982_2022_119_Article_IEq59.gif

12982_2022_119_Article_IEq57.gif

12982_2022_119_Article_IEq54.gif

12982_2022_119_Article_IEq8.gif

Fig. 2